𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial

✍ Scribed by Seidman, A.D.

Book ID
122353258
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
53 KB
Volume
16
Category
Article
ISSN
1043-321X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Gemcitabine, epirubicin and paclitaxel (
Gemcitabine, epirubicin and paclitaxel (GET) vs. 5-fluorouracil, epirubicin and cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomised, multicenter phase iii trial of the Central European Cooperative Oncology Group (CECOG)
✍ T. Brodowicz; S. Beslija; J. Cervek; Z. Mrsic-Krmpotic; I. Tchernozemsky; C. Wil πŸ“‚ Article πŸ“… 2001 πŸ› Elsevier Science 🌐 English βš– 166 KB
P.39 Docetaxel plus epirubicin (DE) vs d
P.39 Docetaxel plus epirubicin (DE) vs docetaxel plus capecitabine (DC) as 1st line treatment in patients with locally advanced and metastatic breast cancer: a subgroup analysis for elderly patients of a multicenter randomized phase III trial from the Hellenic Oncology Research Group (HORG)
✍ Vamvakas, L.; Karampeazis, A.; Ardavanis, A.; Souglakos, I.; Kalbakis, K.; Varda πŸ“‚ Article πŸ“… 2007 πŸ› Elsevier Science 🌐 English βš– 57 KB